Jaffe can also be responsible for client monitoring, technology solutions, data collection, and outcomes research at Options Addiction Treatment, and can present his research in the 39th Annual Research Society on Alcoholism in New Orleans June 25-29, 2016.

Research Society on Alcoholism

“Using ongoing monitoring in outpatient treatment brings management of AUDs nearer to a vintage disease management approach,” stated Adi Jaffe, Ph.D., co-founder and executive director of Options Addiction Treatment. “Telling the general public about these advances will drive the interest in better, more evidence-based treatment tools within the field, therefore enhancing overall outcomes and services in the market.Inch

Jaffe and the co-scientists provided 56 participants within an IOP treatment plan in Los Angeles with breathalyzers at the outset of their program. Breath analyzer assessment schedules were set according to client’s self-report rest schedules, and 3 to 5 checks (M=4) each day were carried out remotely. Breath analyzer data were recorded throughout treatment, which survived between 2 to 6 several weeks (M=3.5 several weeks). Participants received a brief survey to evaluate their satisfaction using the breath analyzer system. Data preparation and analysis was carried out publish treatment.

Alcohol treatment originates a lengthy way from enforced isolation in asylums, and technological advancements are particularly promising when it comes to their ability to improve treatment effectiveness. Promising research compares the practicality, implementation, validity and usage of mobile momentary-assessment breathalyzers inside the context of the intensive outpatient (IOP) strategy to alcohol-use disorders (AUDs).

Results support using emerging measurement technology to enhance alcohol treatment. “The primary contribution in our scientific studies are the development of techniques that will help improve oversight and accountability within treatment without greatly growing costs,” stated Jaffe. “Using technology can improve outcomes in treatment while reducing logistical restrictions and price-prohibitive treatments.Inch

Leave a Comment

Your email address will not be published. Required fields are marked *